Christopher G. Campbell

Partner

Chair, Product Liability and Mass Torts Group

Co-Chair, Product Liability, Mass Torts & Class Actions Group

A 'knack for breaking down difficult science into concepts' and 'creativity and unorthodox tactics' that 'have set him apart.'

— Law360

Emailchristopher.campbell@us.dlapiper.com

Call+1 404 736 7808

Atlanta New York

About

Chris Campbell is the Chair of DLA Piper's Product Liability and Mass Tort practice group, awarded "Practice Group of the Year" in 2025 by Law360, ranked Band 1 by Chambers, and ranked Tier 1 by Legal 500. Clients say, "Chris Campbell is a great team leader. I think he is in large part responsible for building a team of diverse individuals who work excellently together." (Legal 500) He is also Co-Chair of the Product Liability, Mass Torts & Class Actions Group.

A graduate of Harvard Law School, Chris has 25 years' experience in all phases of mass tort, class action, and other product liability complex commercial litigation, serving as global, national, and trial counsel for many global companies across industries. He also advises clients on regulatory, communications, and other strategic matters that impact the clients' business interests or reputations.

Clients say of Chris: "He is great. Period." Others praise the quality of his strategic advice and devotion to client service as "truly indispensable" to their teams, noting their gratitude for "all the help (almost around the clock!) and good advice."

Chris is ranked by Chambers, which highlights client endorsements noting that Chris "gives precise advice and always thinks in the best interests of his clients." that he "will think through the most complex issues very fast," and that he "has great commercial acumen" and "provides great service." (Chambers)

Legal 500 recognizes Chris as a "leading partner" in product liability, mass tort, and class action defense, noting client endorsements that Chris "commands respect," that he "always thinks in the best interest of his clients and always thinks ahead,” and is “always available and keen to share insightful views on complex litigation matters." (Legal 500)

Forbes recently recognized Chris as "best in state" in Georgia, the only product liability lawyer to receive this recognition in the state. He regularly speaks and writes on the topics of product liability, mass torts, and class action litigation, as well as the attorney-client privilege, expert witnesses, pharmacovigilance, trial tactics, and other topics. He is the co-author of the book, Expert Witnesses in Product Liability Cases.

Areas of FocusLitigation, Arbitration and Investigations Regulatory and Government Affairs Product Liability Life Sciences Healthcare

Bar admissionsGeorgiaNew York

EXPERIENCE

Chris is lead global strategic and coordination counsel for Bayer in a global mass tort involving a contraceptive medical device that has spanned five continents and more than a dozen countries. In the litigation, the defense has a near 100% success rate, with more than 150 favorable findings by trial courts, appellate courts, and court-appointed experts. This includes a recent class action trial win in the Supreme Court of Victoria in Melbourne, Australia, which issued a complete defense judgment.
Chris is national trial counsel for Hankook Tire and has successfully tried a number of their product liability cases across the country, including in Arkansas, Missouri, North Carolina, Tennessee, and Virginia.See, e.g., Cone v. Hankook Tire, Case No. 14-CV-01122 (E.D. Tenn.).
Chris is lead national counsel for Bayer in the multi-district litigation involving phenylephrine, which resulted in a complete dismissal by the trial court on federal preemption grounds.See In re Oral Phenylephrine Marketing and Sales Practices Litigation, 2024 WL 4606818 (EDNY Oct. 29, 2024).
Chris is lead counsel for Novo Nordisk in a product liability litigation involving the alleged sharing of insulin pens by a hospital in Connecticut.
Chris serves as global and national counsel for Bayer in product liability and class action matters related to Mirena, which have resulted in complete dismissals in California and Washington, as well as China.
Chris serves as counsel to Pfizer in the multi-district litigation involving contraceptive medication, Depo-Provera.See In re Depo-Provera (Depot MedroxyprogesteroneSee In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, Case No. 25-md-3140 (N.D. Fla.).
Chris also serves as lead national, strategic, and trial counsel on a variety of other product liability, toxic tort, and class action matters for clients in a variety of industries, including automotive, industrial equipment, pharmaceutical, medical device, healthcare, consumer goods, and safety equipment.

Awards

Pro Bono

Lead trial counsel representing the NAACP and other plaintiffs in housing discrimination lawsuit, Fair Housing in Huntington Committee v. Town of Huntington, US District Court for the Eastern District of New York, (2014)

Education

J.D., Harvard Law School, 2000
Harvard Negotiation Law Review
International Law Journal
Civil Rights-Civil Liberties Law Review
Ames Moot Court Competition

B.S., Philosophy and English, Austin Peay State University, 1997
Outstanding Young Alumnus of the Year, 2002

Bylines

Chris is co-author of the book Expert Witnesses: Products Liability Cases (Thomson Reuters 2d ed. 2012), an in-depth guide to expert witness development in all types of product liability and mass tort matters, including pharmaceutical, environmental and toxic torts, automotive, industrial accidents and children's and consumer products. He co-authored the article "Sacking the Monday Morning Quarterback: Tackling Hindsight Bias in Failure-to-Warn Cases," For the Defense (October 2010), for which he received the Defense Research Institute's G. Duffield Smith Outstanding Publication Award. The award honors DRI's most outstanding defense-related article published that year.

His recent publications include:

"Product Liability Worldwatch," Corporate Disputes Magazine, Jan-Mar. 2026 Issue
"Considerations When Invoking The Common-Interest Privilege," Law360, Nov. 25, 2025
"Product Liability: Global Overview," Lexology, Sept. 8, 2025
"Out-of-state companies face increased litigation risk under Illinois's proposed jurisdictional law," DLA Piper Client Alert, June 18, 2025
"Georgia enacts sweeping tort reform and litigation funding laws," DLA Piper Client Alert, 21 May 2025
"Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products," PharmExec.com, April 10, 2025
"Guest Post – More on Defense E-Discovery of Health-Related Data from Plaintiffs' Devices," Drug & Device Law, Feb. 20, 2025
"Turning the Tables: Strategies for Discovering and Using Plaintiffs’ Digital Information in Mass Torts," Defense Research Institute Oct. 2024
"8 Childhood Lessons That Can Help You Be A Better Attorney," Law360, October 10, 2024
"FDA issues new guidance on responding to internet-based drug and device misinformation," DLA Piper Client Alert, Aug. 5, 2024
"Protecting Attorney-Client Privilege and Work Product in a Generative AI World Checklist," Lexis, Feb. 5, 2024
"Learned intermediary doctrine: California Supreme Court case may impact failure-to-warn lawsuits within the state," DLA Piper Client Alert, Jan. 8, 2024